Host of firms act on biopharma firm’s $537 mln HK secondary listing
BY Aparna Sai |
Freshfields Bruckhaus Deringer, Gibson, Dunn & Crutcher, King & Wood Mallesons and DLA Piper have advised Chinese biopharma company Hutchmed on its HK$4.17 billion ($537 million) secondary listing in Hong Kong.